Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label single-arm study of sucroferric oxyhydroxide chewable tablets in adolescents with CKD-associated hyperphosphatemia
CTR20250286Phase 4Active
- Sponsor
- CSL Vifor
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of iron sucrose in hyperphosphatemia, chronic kidney disease (CKD), sponsored by CSL Vifor. Started Feb 2025; status: active.
02
Drugs
iron sucrose
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20250286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250286.